Hepatocellular Carcinoma incidences and risk factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents

<p><span>Table S1: </span><span>Comparisons of baseline clinical characteristics between patients treated with DAA and IFN after propensity score matching.</span></p> <p><span>Table S2: </span><span>Univariate and multivariate cox regression model for HCC after propensity score matching</span><span>.</span></p> <p><span>Table S3: </span><span>Univariate and multivariate cox regression model for early HCC (&lt;3 years)</span><span>.</span></p> <p><span>Table S4: </span><span>Univariate and multivariate cox regression model for late HCC (3-6 years)</span><span>. </span></p> <p><span>Figure S1: Flowchart of patient recruitment.</span></p> <p><span>Figure S2: Scheme for time scale in Cox regression analysis to investigate early HCC and late HCC predictors.</span></p> <p><span>Figure S3: The cumulative HCC incidences stratified by age </span><span><span>&sup3;</span></span><span>60 and &lt;60 years</span><span> (A) in ACLD (B) in non-ACLD</span></p> <p><span>Figure S4: The comparisons of the HCC risks within 3 years (early onset) and after 3 years (late onset). (A) DAA group (B) IFN group. </span></p>